СARDIOPROTECTION IN PATIENTS WITH HYPERTENSION – THE ROLE OF LOSARTAN

• Published in: Rat͡s︡ionalʹnai͡a︡ farmakoterapii͡a︡ v kardiologii Vol. 9; no. 6; pp. 660 - 663
• Main Authors: Chukaeva, I. I., Spiryakina, Ya. G.
• Format: Journal Article
• Language: English
• Published: Столичная издательская компания 01.09.2015
• Subjects: antihypertensive therapy; arterial hypertension; cardioprotection; left ventricular hypertrophy; losartan
• ISSN: 1819-6446; 2225-3653
• DOI: 10.20996/1819-6446-2013-9-6-660-663

In patients with arterial hypertension (HT) heart is affected earlier and more often than other target organs, left ventricular hypertrophy (LVH) develops. Considering the proven link between the presence of LVH and increased cardiovascular risk, the deterioration of the clinical course and prognosis in HT patients, as well as a significant prognosis improvement in patients with LVH decrease, correction of modifiable risk factors (including uncontrolled HT) is getting extremely important. Organoprotective properties of drugs should be taken into account as one of the important parameters in the consideration of antihypertensive therapy. Major studies conducted in recent years have proven cardioprotective and angioprotective properties of angiotensin receptor blocker losartan, so it can be used as first-line therapy in patients with HT and LVH.